116 results about "Immunosuppressive drug" patented technology

Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, immunosuppressive, or other therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the disclosed pharmaceutical compositions.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.

The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2 / g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

The invention discloses an accurate prediction method for a tacrolimus dosage of an organ transplantation patient. The method comprises the following steps: collecting model establishment data including but not limited to patient personal data, tacrolimus clinical medication data based on the organ transplantation patient and gene detection data; carrying out management and statistical analysis on the collected model establishment data; and establishing a tacrolimus dosage model for organ transplantation based on the model establishment data, wherein the model establishment comprises data arrangement, basic structure model, covariable incorporation and model verification. The tacrolimus accurate dosage prediction mathematical model helps clinically and accurately predict the initial medication dosage and dosage adjustment scheme of an individual patient, reduces toxic and side effects caused by too large tacrolimus dosage or the risk of rejection caused by too low tacrolimus dosage of the patient, reduces the occurrence rate of acute rejection reaction and reduces adverse drug events. The prediction method has important significance on accurate application of immunosuppressive drugs for organ transplantation patients; meanwhile, has good economic benefits and social benefits.

The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.

Methods for the diagnosis and treatment of fungal infections caused by microorganisms producing glucosylceramide are provided. In particular, methods for diagnosing or predicting dissemination of a fungal infection from the lungs to the blood stream of a patient are provided. Methods for treating a fungal infection and / or preventing the dissemination of a fungal infection from the lungs to the blood stream or to other organs of a patient, and methods for preventing or treating a fungal infection in a patient by administering a therapeutically effective amount of a fungal glucosylceramide synthase inhibitor to a patient. Such methods are particularly useful for use with patients at risk to develop fungal infections, such as HIV or cancer patients, patients hospitalized in intensive care units, or patients receiving immunosuppressive drugs such as transplant patients.

Methods for monitoring the immune response and predicting clinical outcomes for patients on immunosuppressive drugs (such as transplant patients) are provided. The methods are based on the measurement of an intracellular metabolic marker in lymphocytes (such as ATP) as an indicator of a patient's immune response.

A highly specific homogeneous assay method for an immunosuppressive drug using an immunophilin in a single receptor format is provided. In the simplest format, a single receptor is utilized analogous to a competitive immunoassay whereby an immunophilin is substituted for an antibody, and a competition results between a drug conjugate and the drug analyte for a limited number of immunophilin binding sites. In a microparticle agglutination assay format, an immunophilin is either bound to a particle or in solution. In the case where an immunophilin is bound to a particle, a polyvalent conjugate of the drug analyte is present in solution.

A method is provided for preventing rejection by an immune system of a recipient subject of a tissue transplanted from a donor subject into the recipient subject without the need for long-term administration of non-specific immunosuppressive drugs.